openPR Logo
Press release

Potential Balding Treatment?

03-11-2011 08:46 AM CET | Health & Medicine

Press release from: Mylash

Prostaglandin molecules have been shown to induce the growth and darkening of hair and the eyelash has been particularly studied. Bimatoprost, a prostaglandin, has achieved FDA approval for the treatment of hypotrichosis of eyelash hair (inadequate or not enough eyelashes).

Minoxidil, an over the counter treatment in the UK, is used for male pattern baldness and its mode of action appears to be increased prostaglandin synthesis in the applied areas. This suggests that a prostaglandin analogue could provide better results.

Trials started in January 2011 on the use of bimatoprost for male pattern baldness. Participants are testing the use of bimatoprost solution on balding areas of their heads.

This article was written for www.Mylash.org

To read the complete article visit: https://www.mylash.org/about/articles/bimatoprost-baldness-treatment/

Mylash offers consultation for individuals that feel they have inadequate or not enough enough eyelashes. After completing a medical question, and if deemed appropriate, treatment with a prostaglandin analogue is provided.

The FDA approval mentioned in the article was for bimatoprost and in America, the brand name for this is Latisse.

Mylash is a service for people looking to grow their eyelashes longer, thicker and darker. Mylash provides a free medical consultation and treatment with a drug that has been clinically proven to grow eyelashes.

Mylash
1st Floor
2 Parklands Way
Eurocentral
ML1 4WR

Press contact: info@mylash.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Potential Balding Treatment? here

News-ID: 166004 • Views:

More Releases for FDA

FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility
Peyronie’s Disease Market - Only FDA approved product
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30). Announcing New Design Control Training Courses Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation. GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet
11-09-2016 | Science & Education
GRCTS
FDA online training
Description: Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding